Pharmaceuticals News 10 December 2025

Eli Lilly Stock (NYSE: LLY) in Focus: Retatrutide’s Near-30% Weight-Loss Data, FDA Fast-Track Questions for Orforglipron, and Fresh Analyst Forecasts (Dec. 12, 2025)

Meta description: Eli Lilly (LLY) stock is moving as investors weigh standout retatrutide Phase 3 results, a Reuters report on FDA review timing for orforglipron, and updated Wall Street price targets. Published: December 12, 2025 Eli Lilly and Company stock

12 December 2025

Eli Lilly (LLY) Stock After Hours on December 11, 2025: Retatrutide Breakthrough, $6B Plant — and What to Watch Before Friday’s Open

Eli Lilly and Company (NYSE: LLY) ended Thursday’s session back near record territory as Wall Street digested stunning new weight‑loss data from its experimental obesity drug retatrutide, a massive new U.S. manufacturing investment, and fresh signs of global expansion for

11 December 2025

Biotech News · Earnings Reports · Investing · NYSE:LLY · Pharmaceuticals · Stock Market

Centessa Pharmaceuticals (CNTA) Stock on December 11, 2025: CEO Shake‑Up, Analyst Upgrades and 2026 Orexin Catalysts

Date: December 11, 2025 Centessa Pharmaceuticals plc (NASDAQ: CNTA) is back in the spotlight after a major leadership announcement and a sharp intraday pullback in its share price. On December 11, 2025, the company unveiled a CEO transition that will

11 December 2025

Analyst Ratings · CEO News · Drug Development · NASDAQ:CNTA · Pharmaceuticals · Stock Market

Telix Pharmaceuticals (TLX) Stock: Varian Deal, ProstACT Milestone and Class Actions Redraw the 2025 Outlook

December 11, 2025 Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) is ending 2025 in a paradoxical position: commercially successful, rich in late‑stage oncology assets, but trading near its 12‑month lows amid SEC scrutiny, an FDA setback and a growing stack

11 December 2025

Business News · Investment Analysis · Legal Updates · Pharmaceuticals · Stock Market

Immunovant (IMVT) Stock Jumps After $550 Million Share Offering as Graves’ Disease Launch Comes Into Focus

NEW YORK – December 11, 2025 – Shares of Immunovant, Inc. (NASDAQ: IMVT) were sharply in focus on Thursday after the clinical‑stage immunology company announced a $550 million common stock financing designed to fund development and a potential commercial launch

11 December 2025

Biotechnology · Healthcare News · Investments · NASDAQ:IMVT · Pharmaceuticals · Stock Market

AbbVie Stock (ABBV): HSBC Upgrade, Dividend Hike and New FDA Win Reshape the 2025 Outlook

AbbVie Inc. (NYSE: ABBV) has quietly turned into one of 2025’s standout large‑cap pharma stories. Shares are up roughly a mid‑20% percentage year‑to‑date, outpacing the broader market, powered by booming sales of Skyrizi and Rinvoq, a fresh dividend hike, and

11 December 2025

Dividend Investing · FDA Approvals · Financial News · Pharmaceuticals · Stock Market

Eli Lilly (LLY) Stock After the $1 Trillion Milestone: Latest News, Analyst Targets and 2026 Outlook

On November 21, 2025, Eli Lilly and Company (NYSE: LLY) became the first pharmaceutical group ever to cross a $1 trillion market value, lifted by surging demand for its obesity and diabetes drugs Mounjaro and Zepbound. Reuters+2Financial Times+2 Since then,

11 December 2025

Financial News · Investing · Market Analysis · NYSE:LLY · Pharmaceuticals · Stock Market

Pfizer (PFE) Stock Premarket Today, Dec. 11, 2025: Marshall Wace Exit, Obesity Drug Deals and 2026 Guidance in Focus

Pfizer (NYSE: PFE) heads into Thursday’s session with its share price hovering around yesterday’s close, as investors digest a flurry of news on cost cuts, obesity drug deals, and a big hedge fund trimming its stake. As of around 6:05

11 December 2025

Company Earnings · Health Industry · Investment News · NYSE:PFE · Pharmaceuticals · Stock Market

Pfizer Stock Today: Obesity Deal, Cancer Breakthroughs and Job Cuts Shape PFE’s 2025 Outlook

As of the session on 10 December 2025, Pfizer Inc. (NYSE: PFE) is trading around $25.5 per share, up modestly on the day and still far below its 2021 peak. The stock now combines a high dividend yield of roughly

10 December 2025

Business News · Cancer Research · NYSE:PFE · Obesity Treatments · Pharmaceuticals · Stock Market

Olema Pharmaceuticals (OLMA) Stock Hits New 52‑Week High on December 10, 2025: What Investors Need to Know

Published: December 10, 2025 Olema Pharmaceuticals Stock Rallies to Fresh Highs Olema Pharmaceuticals, Inc. (NASDAQ: OLMA), which now brands itself as Olema Oncology, is having another breakout session on December 10, 2025. During Wednesday’s trading, OLMA: Over the past 12

10 December 2025

Company News · Investor Tips · Market Trends · Pharmaceuticals · Stock Performance

Merck (MRK) Stock on December 10, 2025: Price Action, Dividend Catalyst, Analyst Targets and the Keytruda Question

Merck & Co., Inc. (NYSE: MRK) stock is treading water just below the $100 mark on Wednesday, December 10, 2025, as investors weigh a rich pipeline and fresh analyst upgrades against looming patent and pricing pressures. The day’s news flow

10 December 2025

Analyst Insights · Dividend Investing · Market Trends · NYSE:MRK · Pharmaceuticals · Stock Analysis

Johnson & Johnson (JNJ) Stock on December 10, 2025: Pipeline Breakthroughs, Talc Risks and What Analysts Expect Next

Updated: December 10, 2025 Johnson & Johnson (NYSE: JNJ) is trading near fresh highs as investors weigh powerful growth drivers in oncology and immunology against a still‑messy overhang from talc litigation. As of late trading on December 10, 2025, JNJ

10 December 2025

Company News · Financial Forecasts · Investment Analysis · NYSE:JNJ · Pharmaceuticals · Stock Market

Pharmaceuticals News 10 December 2025 - 12 December 2025